Introduction
============

Hepatitis B virus as a member of the *Hepadnaviridae* family is responsible for acute and chronic hepatitis in humans. While there are approved anti-viral drugs and vaccine, HBV infection remains as a main global public health challenge, which is reported to exist in more than 200 millions of people ([@B11]). HBV virions are small and composed of ∼3.2 kb partially double-stranded, relaxed circular DNA. The virus genome encodes four pre-genomic (serves as the template for genome synthesis), surface antigens (large, medium, and small), core (HBe and HBc), and trans-activator x (HBx) coding sequences.

In chronically infected individuals, the serum levels of HBsAg can be as high as 400 μg/mL with domination of non-infectious SPVs. The HBV SVPs are composed of large and small surface antigens ([@B22]). Most of the viral particles are incomplete spherical and filamentous-like particles either containing viral genome (single stranded DNA, RNA, and RNA--DNA hybrids) or empty capsids ([@B17]). It is important to mention that approximately one of 10,000 viral particles is infectious. The SVPs are involved in disease progression and immune modulation in chronic carriers. Importantly, HBsAg carriers in cHBV infection have 25--37% increased risk for developing HCC ([@B27]). Additionally, serum HBsAg level is correlated with intrahepatic HBV replication and transcription in HBeAg negative cHBV carriers ([@B31]; [@B47]). Therefore, it is believed that seroconversion of HBsAg in chronic infection can be a promising approach for cHBV treatment ([@B41]).

Although the current FDA approved HBV treatments such as Lamivudine, Adefovir dipivoxil, Entecavir, Telbivudine, and IFN-α improve the anti-viral immune responses, they have a short-lasting, toxic, and high-cost limitations. Moreover, emerging of drug resistance strains is a major problem of the current drug regimen. Additionally, there are several reports of pre-existing of drug-resistant conferring substitutions in HBV polymerase ([@B15]; [@B36]; [@B13]). In order to decrease the adverse effects of current HBV treatment, novel therapeutics have focused on stimulating host immune responses ([@B57]; [@B5]; [@B26]). In this regard, preclinical try-outs of TLR-7 agonist, Vesatolimod (GS-9620), has shown promising interferon-dependent anti-HBV effect ([@B32]; [@B45]; [@B4]). In a phase II, double-blind, randomized, placebo (PBO)-controlled study of the drug on cHB patients, it was shown that the GS-9620 was safe and well-tolerated in patients with cHB ([@B21]). However, a functional cure will obtain trough HBsAg seroconversion. Current anti-HBV agents reduce viral replication and do not affect HBsAg levels in blood ([@B35]). This may also restore the irresponsiveness of anti-HBV immune responses induced by HBsAg-bearing SVPs ([@B51]). Here, we discussed various potent compounds targeting HBsAg, their actions, and advantages or disadvantages, which can be used in combination with other therapeutics in the future (**Table [1](#T1){ref-type="table"}**).

###### 

HBsAg inhibitors, their targets, and mechanism(s) of action.

  Name                                  Target                            Mechanism                                                           cccDNA existence   Viral replicative intermediate   HBsAg secretion^∗^   Research phase   References
  ------------------------------------- --------------------------------- ------------------------------------------------------------------- ------------------ -------------------------------- -------------------- ---------------- ------------------------
  **Natural products**                                                                                                                                                                                                                  
  Osthole                               HBsAg                             HBsAg glycosylation                                                 NA^∗∗^             NA                               No                   Nonclinical      [@B19]
  *Cler. inerme*                        HBsAg                             Unknown                                                             No                 NA                               No                   Nonclinical      [@B42]
  *Clem. sinensis*                      HBsAg                             Unknown                                                             No                 NA                               No                   Nonclinical      [@B42]
  OjF                                   HBV DNA polymerase                Hypothetical inhibition of viral polymerase                         NA                 Reduced                          No                   Nonclinical      [@B62]
  Hyperoside                            Cellular targets                  Unknown                                                             NA                 Reduced                          No                   Nonclinical      [@B64]
  Alison A derivates                    HBV DNA polymerase                Hypothetical inhibition of viral polymerase                         NA                 NA                               No                   Nonclinical      [@B70]
  PEI                                   Cellular factors                  Unknown                                                             NA                 NA                               No                   Nonclinical      [@B20]
  Luteolin-7-*O*-glucoside              Cellular factors                  Reducing ROS release                                                NA                 Suppressed                       No                   Nonclinical      [@B7]
  **Small molecules**                                                                                                                                                                                                                   
  HBF-0259                              Cellular HBsAg secretory factor   Hypothetical cellular secretory factors and glycosylation machine   Yes                Yes                              No                   Nonclinical      [@B9]; [@B43]
  BM601                                 Unknown                           Interfering HBsAg aggregation in trans-Golgi apparatus              Yes                Yes                              No                   Nonclinical      [@B66]
  Nicotinamide                          SIRT1                             HBV promoters modulation, HDAC inhibitor                            NA                 No                               No                   Nonclinical      [@B33]
  NJK14047                              p38 MAPK                          P38 MAPK inhibition                                                 Reduced            No                               No                   Nonclinical      [@B24]
  **Interfering RNAs**                                                                                                                                                                                                                  
  S-targeted siRNA                      Viral S-coding transcripts        RNA interference                                                    NA                 No                               No                   Nonclinical      [@B25]
  HBVU6.2                               Viral S-coding transcripts        RNA interference                                                    No                 No                               No                   Nonclinical      [@B41]
  pGE-HPV2                              HBV DNA polymerase                Hypothetical inhibition of viral polymerase                         Yes                No                               No                   Nonclinical      [@B37]
  ARC-520                               All viral transcripts             RNA interference                                                    NA                 No                               No                   Phase I/II       [@B29]; [@B68]; [@B51]
  **Other types of HBsAg inhibitors**                                                                                                                                                                                                   
  Mycophenolic acid                     Monophosphate dehydrogenase       HBV polymerase suppression through guanosine depletion              Undetectable       Reduced                          No                   Nonclinical      [@B14]
  C4D2-BsAb                             HBsAg                             Binding to and induce conformational changes within HBsAg           NA                 NA                               No                   Nonclinical      [@B55]
  HNF1α                                 NF-κB p65 and LHBsAg              NF-κB activation                                                    NA                 No                               No                   Nonclinical      [@B34]

∗

No one of inhibitors have reported completely and long-lasting suppression of HBsAg.

∗∗

Based on the mechanism of action of the inhibitor, it is not applicable or not reported in the study.

Different Classes of HBsAg Inhibitors
=====================================

Natural Products
----------------

Since conventional chemical drugs' adverse effects and drug resistance are known, natural products and related bioactive compounds have gained increasing attention from physicians and medical researchers. Natural products as a class of traditional medicine are sophisticated and time-honored form of healthcare in many countries.

In Chinese medical herb, Osthole extracted from *Angelica pubescens* Maxim (Du Huo) root has screened for HBsAg secretion inhibition ([@B19]). In MS-G2 and Huh-7 cells, Osthole concentrations from 5 to 20 μg/mL have shown remarkable HBsAg secretion inhibition from 23.5 to 60.5% and 18.4 to 70.1% after days 3--6, respectively ([@B19]). Results of the study on Osthole suggest specific post-transcriptional inhibition of both small and middle HBsAg secretion^8^. The study revealed that hyper-glycosylation of HBsAg is a mechanism underlying Osthole action as a potent inhibitor of HBsAg ([@B19]).

Terrestrial plants' extracts have been evaluated for their anti-HBV activities ([@B42]). Of 19 terrestrial plants' extracts from different parts of the herb, some have shown more than 50% HBsAg secretion inhibition. Of which, two extracts from *Clerodendrum inerme* (family Verbenaceae) with 85% and *Clematis sinensis* (family Ranunculaceae) with almost 60% HBsAg inhibition were reported to be strongest with no cytotoxicity in HepG2.2.15 cells ([@B42]). While the compounds have suppressed HBV replication, the extracts had no long-lasting inhibitory effects on HBsAg secretion.

The active compound of OjF has been used widely for the treatment of a broad range of symptomatic human diseases such as HBV infection ([@B62]). The OjF has suppressed HBsAg secretion in a dose- and time-dependent manner. There were no remarkable side effects in HBV-infected ducklings treated with OjF as well ([@B62]). The hypothetical mechanism of OjF suggests that it may prevent HBV DNA polymerase activity and subsequently HBsAg transcription and production ([@B62]). While animals' treatment with \> 50 g/L of OjF has shown extended HBV reproduction suppression, 3 days after OjF cessation, HBV replication restored. Interestingly, viremia has also decreased as high as 64% following OjF treatment in animal models.

Hyperoside (quercetin-3-*O*-galactoside), a flower extract of *Abelmoschus manihot* (L) medik, is another natural product with anti-HBV activity ([@B64]). This edible herb has a broad range of medication usage. The HBsAg producing cell line, HepG2.2.15, and infected ducklings were used for investigating anti-HBV activity of hyperoside ([@B64]). The HBsAg secretion inhibition rates were 82.27% at the dose of 5 mg/L. Non-toxic dose of hyperoside has shown liver histopathological improvements indicating reduced levels of viremia ([@B64]). However, the mechanism of action of hyperoside-induced HBsAg production suppression is unknown.

The natural product Alisol A's is a protestane-type triterpens. Hydroxyl (OH)-substituted Alisol A lead compounds have anti-HBsAg activities ([@B70]). Future hit-to-lead optimization of protestane-type triterpene compounds would be a promising anti-HBV achievement. Like other FDA-approved HBV polymerase inhibitors, Alisol A derivates might have an identical mechanism of action ([@B70]). However, further analysis is needed to understand its exact role in HBsAg secretion inhibition. Accordingly, neither viral DNA synthesis nor production of HBV transcripts had not been investigated.

There are further studies, which have been worked on the natural products against HBV infection. A basic, thermo-stable, polypeptide PEI extracted from Jelly Fig Achenes (Ficus awkeotsang Makino) has been studied for its anti-HBsAg expression potential ([@B20]). In that study, two cell lines bearing endogenous and integrated forms of HBV genome, Hep-3B and Huh-7, have been used for assessing HBsAg expression in the PEI treated supernatants. In average, 80% decreased of HBsAg gene expression had observed *in vitro*. Meanwhile, there was a decreased in the antigen secretion inhibition in Hep-3B containing endogenous form of the virus genome ([@B20]). The main biological function of PEI is known to induce programmed cell death through the intrinsic caspase-dependent pathway. The mechanism of action underlying HBsAg secretion inhibition in supernatants under PEI treatment is unknown. Furthermore, analysis of the different viral processes, including DNA replication, RNA transcription, and viral/SVP production, has also needed to be investigated ([@B20]).

Active compound, Luteolin-7-*O*-glucoside, extracted from leafy vegetable lettuce (*Latuca satica L.*) has been shown to significantly reduce HBsAg production (\>82%; [@B7]). The plant extract had no cellular toxicities at lower concentrations. The viral RNA is a biomarker for activity of HBV transcription ([@B7]). Accordingly, the viral RNA was significantly reduced (43.9%), which was consistent with reduced HBV replication ([@B7]). Inoculation of Luteolin-7-*O*-glucoside along with 3TC or IFN-α has been shown to have synergistic anti-HBsAg production effects. However, it was not significantly differing from that of the extract alone ([@B7]). HBsAg secretion inhibition mechanism of Luteolin underlies beneath the ability of the compound to inhibit mitochondrial production of ROS ([@B7]), indicating the role of ROS in HBV lifecycle.

Discoveries of anti-viral natural products are still an expanding approach. The studies clearly indicate a potential utility of traditional herbal medicine in cHBV treatment, especially in HBsAg inhibition. Further studies are needed to improve and specify their potencies and uncover mechanisms of the products' activities. In this regard, studies in animal models would be helpful.

Small Molecules
---------------

Drug discovery approach is a promising strategy for finding novel anti-viral inhibitors ([@B30]). High-throughput screening of four widespread small molecule libraries composed of over 80,000 drug-like leads, led to identification of potent anti-HBV compound, HBF-0259 ([@B9]). In a time- and dose-dependent manner, HBF-0259 specifically targets all forms of HBsAg in HBsAg expressing cells, HepH2.2.15 and HepDE19 ([@B9]). This mechanism of action may be underlain beneath of its interaction with cellular secretory or HBsAg post-translationally modifying factors ([@B9]; [@B43]). Long-term treatment assay of HBF-0259 has been shown no traceable level of glycosylated forms of HBsAg in the supernatant ([@B9]). Meanwhile, only intracellular non-glycosylated forms of HBsAg have been observed. This indicates that HBF-0259 may target cellular counterparts involved in HBsAg modification and secretion ([@B43]). Moreover, HBF-0259 had no significant effect on HBV DNA replication.

Benzimidazole and its derivatives have therapeutic potency, including anti-microbial, anti-viral, anti-tumoral, and anti-allergic effects ([@B61]; [@B10]). BM601 is a Benzimidazole derivative with an ability to inhibit HBsAg secretion ([@B66]). BM601 inhibits HBsAg secretion and subsequently HBV viral particle formation *in vitro*. HBV DNA replication, transcription, and nucleocapsid synthesis were not altered following BM601 treatment in HepG2.2.15 cell line. Also, it does not change cellular protein synthesis, ROS stimulation, and ER stress ([@B66]). Importantly, BM601 induces HBsAg secretion inhibition and subsequently HBV viral particle formation through alteration of HBsAg displacement with high cytoplasmic distributions, but it does not alter HBsAg glycosylation patterns ([@B66]).

Nicotinamide is the active form of nicotinic acid, niacin (vitamin B3), and a precursor of NAM adenine dinucleotide (NAD^+^). NAM is the most potent inhibitor of SIRT1 with known anti-viral effects ([@B28]). Different concentrations of NAM have been used for evaluating anti-HBV activity in both HepG2.2.15 and HepAD38 cells as well as HBV transgenic mice model ([@B33]). Furthermore, suppression of HBsAg expression was dose-dependent following NAM treatments. Highest inhibition of HBsAg expression was at 16 mM NAM concentration with production of no viral particles *in vitro* ([@B33]). Luciferase reporter assay has been indicated direct interaction of NAM with all four HBV, SpI, SpII, core, and X promoters ([@B33]). Indirectly, NAM was found to suppress HBV transcription and replication by reduction in cellular transcription factors such as the AP-1, C/EBPa, and PPARα levels ([@B33]).

Biphenylamid non-nucleoside derivate, NJK14047, is active in inhibition of p38 MAPK ([@B24]). Accordingly, NJK14047 has been shown the greatest p38 MAPK inhibitory effect highly correlated (85%) with HBsAg secretion inhibition. HBsAg secretion has shown to be inhibited in both HBV integrated and transient transfected HepG2 cell lines as high as 70% and 90%, respectively. Similar HBsAg secretion inhibition has been also observed in a cell line infected with HBV expressing NTCP after NJK14047 treatment ([@B24]). Higher dose of NJK14047 small molecule was needed for obtaining sufficient HBV viral DNA, mRNA, and viral particle production ([@B24]). The novelty of the study was to target cellular factors involved in HBV infection.

Cyclophilin A inhibitors are known to have anti-viral properties ([@B8]). In this regard, [@B52] have been shown potential of Cyclosporin (Cs) derivates to inhibit HBV entry. In that study, which was conducted to produce anti-HBV agents to inhibit HBV, it was observed that Cs derivates are potent to prevent viral entry through NTCP pathway ([@B52]). Effects of the derivates (SCY450 and SCY995) on HBV entry were evaluated in cell line HepG2-hNTCP-C4 over-expressing NTCP. The compounds were not immunosuppressant. They also had no effect on HBV replication. In a dose- and time-dependent manner, the HBsAg level was significantly decreased. The advantage of the derivates was in their role to target NTCP without affecting its main function, bile acid transportation. The compounds have also been potentiated to prevent entry of several HBV genotypes (A, B, C, and D). In addition, the derivates could inhibit HBV variant containing three revers-transcriptase substitutions conferring entecavir resistance ([@B52]).

Considering that small molecules inhibit HBV infection and HBsAg secretion, further optimization may provide clinically applicable therapies. In this regard, discoveries of small molecules targeting known cellular factors involved in HBV pathogenesis or the virus itself are much target-specific and easy-to-obtain procedure. Optimization of this potential anti-HBV drug-like compound would be promising in the future of HBV therapy.

RNA Interference
----------------

There is accumulating data on the RNA interference utility in HBV treatment. HBsAg targeted siRNAs have been evaluated in a novel NMRI animal model of HBV infection in order to suppress the antigen production ([@B25]). Results of the study have shown a significant decrease of HBsAg and HBeAg expression. As an important therapeutic benefit of using siRNA is that the siRNAs are well constructed to target the virus regulatory elements. However, short-lasting effect of the presented siRNA (11 days) is a disadvantage, which may be resulted from inefficient transfection of mice hepatocytes (10%; [@B25]).

HBV replication supportive Huh-7 cells and two immunocompetent C57BL/6 and immunocompromised NOD SCID mice models transfected with HBV pTHBV2 clone have been used for investigation of anti-HBV effect of shRNAs ([@B41]). In that study, four potent double-stranded shRNAs have been designed to target HBsAg transcription (HBVU6no.1--4). Of those, only HBVU6no.2 showed significant HBsAg suppression *in vitro* (94 ± 0.59%) in a time-dependent manner. In NOD mice with no interfering immunity, treatment with HBVU2no.2 has reduced HBsAg level more than 85% in 1 week. The results were accompanied with no observation of cccDNA in transfected mice and no evidence of detectable levels of HBV replicative intermediates ([@B41]). This report presents a rational evidence of anti-HBV approach through targeting the viral transcripts and HBV suppression in both *in vivo* and *in vitro*.

In the last decade of the cHBV infection therapy, ARC-520 RNA interference therapy is promising because of accelerating HBsAg seroclearance and host immune reconstitution ([@B68]). Single intravenous injection (2 mg/kg) of the siRNA in HBV mice models showed a good reduction in HBV viral load and HBsAg secretion with no toxicity ([@B29]). Moreover, in chronically infected adult non-human primates, HBsAg decreased up to 96% with the same dose and a second boost of ARC-520 (3 mg/kg). This result was promising in big-sized cHBV animal models. However, after 30 days of first injection, HBsAg levels have rescaled, partly due to short half-life of ARC-520 siRNAs components ([@B29]; [@B51]). This disadvantage may come along with the fact that by increasing body weight, the dose of the siRNA should be heightened, which may cause toxicity. This concern has been answered in phase I clinical study of ARC-520, where hypersensitivity reaction (resolved by oral antihistamine administration) and no further cytotoxicity were observed in 36 healthy volunteers ([@B51]). Further adverse effects were transient or just because of subject's pre-dose issues. In the next double-blinded, PBO-controlled phase IIa study, single intravenous administration of 1 mg/kg, 2 g/kg, and 3 mg/kg of ARC-520 were done to the three cohorts of chronically HBV-infected adult patients, respectively ([@B68]). In that study, 31%--51% HBsAg declines were observed in cohort 1 and 2 on day 85, respectively, and the cohort 3 is still blinded ([@B68]).

In a study, authors have used a 29-base sequence stretch of HepG2.2.15 genome for the design of siRNA (pGE-HPV2) targeting HBV genome ([@B37]). pGE-HPV2 was potent with HBsAg secretion inhibition rate of 80% in a time-dependent manner (50% after 24 h post-transfection; [@B37]). The pGE-HPV2 is designed to target HBV DNA polymerase. This molecule may prevent viral replicase production and subsequently decrease HBsAg gene transcription. Further information from this study is not known. However, it could be concluded that the siRNA may interfere with viral replication.

Employment of siRNAs in HBV infection inhibition has been considered as a promising approach. This is supported by two clinical trial phases of ARC-520. The advantage of ARC-520 over other mentioned siRNAs is that ARC-520 targets all forms of HBV transcripts, and it is well designed to localize into hepatocytes efficiently with minimized cytotoxicity. The most important disadvantage of RNA interference may be the incidence of scape mutant strains. However, ARC-520 with formulation of two multisite-targeting siRNAs has broad-range HBV genotype coverage and reduces the chance of scape mutant emergence. This might ultimately lead to clinical therapy for HBV infection.

Other Classes of HBsAg Secretion Inhibitors
-------------------------------------------

There are also other types of HBsAg secretion inhibitors. Immunosuppressive Mycophenolate (MMF) active compound, MPA, is a monophosphate dehydrogenase (MP-DH) inhibitor. It can inhibit HBsAg secretion in HepG2.2.15 cell line at low concentrations ([@B14]). The mechanism of HBsAg secretion inhibition by MPA underlies its potential to depleting cellular exogenous guanosine source (GTP) and subsequently viral DNA polymerase inactivation ([@B14]).

Two mAbs C4G4 and D2H2 have been demonstrated to target two circularized epitopes within the HBsAg loop domain ([@B55]). A bispecific antibody, C4D2-BsAb, engineered from C4G4 and D2H2 mAbs has been shown to recognize two HBsAg loop domain epitopes in one time. This prevents interaction of HBV with its cellular surface receptor(s). Accordingly, pre-treatment of HepRG cells and treatment of cell line producing HBsAg, PLC/PRF/5, have shown remarked decrease of HBsAg secretion ([@B55]). C4D2-BsAb targets circularized epitopes within HBsAg loop domain, and it can be used for prevention therapy approaches ([@B55]). However, investigation of infected chimpanzees revealed short (few days) lasting of HBsAg suppression with antibodies ([@B16]). The C4D2-BsAb action may be through induction of conformational changes as well as conflicting with virus--receptors interactions.

Other immune modulators have also shown to have anti-HBV activity. Accordingly, HNF1α, an LETF, can downregulate HBV gene expression and replication ([@B34]). Indirect effect of HNF1α in reduction of HBsAg secretion and viral particle production is through upregulation of p65, a nuclear marker for NF-kB activation, and downregulation of p65 inhibitor HDAC2, *in vitro* ([@B34]). Viral infection activates NF-kB signaling, which leads to nuclear accumulation of NF-kB and downstream gene transcription, triggering cellular events like apoptosis ([@B54]; [@B48]). It can be concluded that apoptosis induced by HNF1α could be a hypothetical mechanism underlying HBsAg secretion inhibition from infected cells.

Conclusion and Future Perspectives
==================================

According to the meeting of American Association for the Study of Liver Diseases and the European Association for the Study of the Liver ([@B40]), cHBV cure defines as loss of HBsAg in serum, eradication of integrated viral DNA and residual cccDNA, and resolution of damaged hepatocytes with decreased risk of HCC ([@B40]). The infected hepatocytes of patients with cHBV are reservoirs for active/inactive cccDNAs and integrated form of viral double-stranded linear DNA, which both produce HBsAg and subsequently SVPs ([@B1]; [@B18]). It seems that using novel potent and non-toxic HBsAg inhibitors might restore exhausted immune response, which induced by SVPs ([@B51]).

Further obstacles beneath HBV infection treatment underlie in frequent drug resistance mutants. There are several reports regarding to drug resistance mutants in treatment-naïve patients ([@B15]; [@B46]; [@B53]; [@B56]; [@B36]; [@B50]; [@B49]; [@B60]; [@B13]). This brings burden of screening, defining new anti-viral regimen, and more importantly transmission chance of mutant strains. Using novel non-nucleos/tide therapeutics may improve the need of mutants screening. However, the rise of scape mutants after siRNAs therapy may still be a concern ([@B41]).

For achieving to the ideal of HBsAg clearance, sustained HBsAg secreting cell lines and animal models have been used. Meanwhile, HBsAg secretion inhibition levels are always significantly lower in cell lines with integrated viral genome than that in other transiently transfected hepatoma cells ([@B24]). This is because of constant expression of HBsAg, which is independent of virus itself. It also implies the importance of HBsAg secretion inhibition in such models for evaluating the efficiency of novel HBV therapeutics. One other limitation for the study of HBV pathogenesis is the unavailability of inexpensive, easy-to-handle, small animal models ([@B25]). Therefore, there are some advances in development of such animals ([@B25]; [@B62]; [@B33]). This provides better insight of HBV infection and therapeutics approaches. Animal models like C57BL/6 and NMRI mice, hatched ducklings, and chimpanzees are used for anti-HBV therapeutics. However, big-size chronically infected chimpanzees are suitable animal models for development and evaluation of novel potent anti-HBV agents ([@B62]; [@B69]).

In this review, HBsAg inhibitors were clustered into small molecules, natural products, interfering RNAs, and another group contained immunological therapeutics. Based on the mechanism of action, some factors are targeting viral components, including siRNAs, shRNAs, HBF-0259, MPA, pGE-HPV2, NAM, C4D2-BsAb, OjF, and Alisol A. Further inhibitors, including Osthole, BM601, NJK14047, Luteolin-7-*O*-glucoside, SCY450 and SCY995, and HNF1α, all have cellular targets. Five other inhibitors' (PEI, *Cler. inerme*, *Clem. sinensis*, BM601, and hyperoside) mechanisms of action are still unknown (**Figure [1](#F1){ref-type="fig"}**). There is a novel HBV receptor inhibitor, Myrcludex B, that targets NTCP but it has no effect of HBsAg secretion ([@B59]; [@B2]). The compound is in pre-clinical trial and shows promising results ([@B3]). The discussed compounds are not all introduced to human trial, and some may never rich in. This is because of some critical checkpoints at which the virus activities should be evaluated: (1) decreasing HBsAg level must be correlated to reduction of serum HBV pgRNA levels, implicating downregulated residual cccDNA activities and (2) restoration of cellular immunity targeting infected hepatocytes containing different forms of HBV genome ([@B39]; [@B6]).

![The mechanisms of HBsAg inhibitors' action. Hepatitis B virus life cycle is illustrated. Inhibitors are named in blue. The integrated form of HBV is shown as dark blue within host genome (blue dashed line). The bold viral transcripts are those that are also transcribed from the integrated viral genome ([@B58]).](fmicb-09-00662-g001){#F1}

HBsAg inhibitors are discussed in detail (**Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). In addition, there is this believe that host immune restoration followed by HBsAg seroconvergence would be the functional HBV cure. Therefore, the present study did not attend much about other aspects of the virus pathogenesis factors like HBeAg and HBcAg. Furthermore, different classes of therapeutic anti-cHBV vaccine in human trials are reviewed in ([@B12]).

In conclusion, small molecules and natural products are well-tolerated anti-HBsAg candidates, which if possible might provide a better insight on HBV--cell counterpart interactions and pathogenesis in the future. As reviewed here, no HBsAg inhibitors have been enabled to suppress secretion of the antigen completely. This might be due to residual cccDNA and or integrated viral genome. Therefore, a "complete functional cure" will achieve through both suppression of HBsAg and elimination of infected hepatocytes. Because of genomic nature of HBV, interfering RNAs by targeting overlap regions of HBV genome will have promising results. Further therapeutics like anti-HBsAg aptamers neutralizing viral particles ([@B65]), HBV receptor inhibitors ([@B23]; [@B63]; [@B52]), and CRISPR-Cas9 ([@B38]; [@B44]; [@B67]) targeting integrated and cccDNA genome would be the ideal therapies in the future.
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